Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort.
Saved in:
| Title: | Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort. |
|---|---|
| Authors: | Lédinghen, Victor1 (AUTHOR) victor.deledinghen@chu-bordeaux.fr, Lusivika‐Nzinga, Clovis2 (AUTHOR), Bronowicki, Jean‐Pierre3 (AUTHOR), Zoulim, Fabien4 (AUTHOR), Larrey, Dominique5 (AUTHOR), Metivier, Sophie6 (AUTHOR), Tran, Albert7,8,9 (AUTHOR), Marcellin, Patrick10 (AUTHOR), Samuel, Didier11 (AUTHOR), Chazouillères, Olivier12 (AUTHOR), Chevaliez, Stephane13,14 (AUTHOR), Dorival, Celine2 (AUTHOR), Fontaine, Hélène15 (AUTHOR), Pawlotsky, Jean‐Michel13,14 (AUTHOR), Carrat, Fabrice2,16 (AUTHOR), Pol, Stanislas15 (AUTHOR) |
| Source: | Journal of Viral Hepatitis. Oct2020, Vol. 27 Issue 10, p964-973. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 13520504 |
|---|---|
| DOI: | 10.1111/jvh.13321 |
